Why I invested over 600 euros in Mind Medicine $MNMD (-0,4 %) and see 10x potential 🍄
In my latest investment, I spent 600 euros on 90 shares of Mind Medicine (MindMed), and I'd like to explain why I think this move is extremely promising.
Mind Medicine (MindMed) 🧠💊
- Founded:** 2019, New York City
- CEO:** Robert Barrow
- Stock exchange abbreviation:** MMED, MNMD
- **Website:** mindmed.co
- **Mission:** Development of psychedelic drugs for mental disorders
- **Products:** LSD, MDMA, Ibogaine, 18-MC
### The vision of Christian Angermayer
A decisive reason for my trust in MindMed is Christian Angermayer. He is a visionary entrepreneur and investor who has a clear idea of how psychedelic therapies can revolutionize the medical landscape. His successes to date and his intensive involvement in this sector give me confidence that MindMed is on the right track.
### A controversial but promising field
While large pharmaceutical companies are often skeptical about psychedelic therapies, this is exactly why MindMed is so intriguing. The company operates largely under the radar, giving it the freedom to conduct groundbreaking research that is often shunned by traditional pharmaceutical companies.
### Research projects and clinical trials
MindMed is conducting several clinical trials to investigate the efficacy and safety of psychedelic substances. These studies have the potential to fundamentally change the way we treat mental health problems. Should MindMed make significant progress, the results could not only be beneficial to patients, but could also be hugely accretive to the company.
### Project highlights
- **Project Lucy:** Focus on LSD
- **Project Layla:** Research into 18-MC
### Transparency and expertise
What also convinces me are the reviews and analyses that MindMed regularly receives from leading specialists in the field of psychedelic research. These expert opinions reinforce my decision that this company has a solid scientific foundation.
### Share valuation
- **Current share price:** approx. $7.46
- **Target price:** $25.86 (+246.65%)
- **Highest price target:** $36 (+382.57%)
- **Recommendations:** Strong buy recommendations from 8 analysts
I will continue to document my journey and investments. If you are interested in more details and updates, you can follow my videos on these topics on tiktok https://vm.tiktok.com/ZGetMsGkh/
---
**Further information:**
MindMed Website: www.mindmed.co
---
Disclaimer: This is not investment advice. I am merely sharing my personal experiences and insights. Everyone should do their own research before making any investment decisions.
I work with Christian Angermayer, but this post is not paid. I believe in the project privately and am sharing my personal involvement here.
---
Have you had any experience with psychedelic substances? How do you feel about investing in this area? Feel free to join the discussion and share your opinions!
---
For more insights and transparent trades, follow me here on getquin.
